
    
      The primary aim of the study is to develop acute care safety and pharmacokinetic profiles of
      riluzole in patients who have sustained a acute traumatic spinal cord injury. Secondary
      objectives are to conduct exploratory analyses of functional outcomes for purposes of
      planning a subsequent Phase II randomized study of the efficiency of Riluzole for the
      treatment of acute traumatic spinal cord injury.
    
  